Table 1. Treatment effect for progression-free and overall survival according to the level of expression for each biomarker.

		Treatment effect (C vs CB+CBM)a
		0, 1+		2+		3+	Interaction Pb
Biomarker	n	HR (95% CI)	n	HR (95% CI)	n	HR (95% CI)	Pc	Pd	Pe
Progression-free survival
VEGF-A	64	0.44 (0.26–0.76)	141	0.64 (0.44–0.93)	62	0.84 (0.48–1.48)	0.15	0.22	0.30
VEGF-B	105	0.47 (0.30–0.73)	91	0.80 (0.51–1.24)	71	0.80 (0.46–1.38)	0.11	0.16	0.69
VEGF-C	113	0.55 (0.37–0.83)	83	0.60 (0.36–1.00)	70	0.72 (0.43–1.21)	0.40	0.78	0.19
VEGF-D	32	0.22 (0.08–0.55)	117	0.67 (0.45–1.00)	110	0.77 (0.50–1.17)	0.02	0.04	0.04
VEGFR-1	85	0.42 (0.26–0.68)	89	0.95 (0.57–1.57)	87	0.65 (0.41–1.04)	0.21	0.49	0.55
VEGFR-2	101	0.51 (0.33–0.79)	102	0.60 (0.37–0.96)	62	0.84 (0.50–1.44)	0.19	0.35	0.95
Overall survival
VEGF-A	64	1.00 (0.53–1.86)	141	0.75 (0.49–1.14)	62	1.18 (0.63–2.21)	0.74	0.98	0.86
VEGF-B	105	0.55 (0.33–0.91)	91	1.12 (0.67–1.85)	71	1.30 (0.71–2.38)	0.02	0.004	0.46
VEGF-C	113	0.56 (0.36–0.89)	83	1.18 (0.65–2.16)	70	1.40 (0.75–2.58)	0.02	0.05	0.36
VEGF-D	32	0.35 (0.13–0.90)	117	0.82 (0.52–1.30)	110	1.28 (0.79–2.09)	0.01	0.02	0.24
VEGFR-1	85	0.41 (0.24–0.69)	89	1.37 (0.78–2.40)	87	1.53 (0.86–2.73)	0.001	0.002	0.06
VEGFR-2	101	0.48 (0.30–0.79)	102	1.12 (0.66–1.90)	62	1.67 (0.87–3.21)	0.003	0.004	0.93

Abbreviations: C=apecitabine; CB=capecitabine and bevacizumab; CBM=capecitabine, bevacizumab, and mitomycin; CI=confidence interval; HR=hazard ratio; VEGF=vascular endothelial growth factor; VEGFR=vascular endothelial growth factor receptor.

^aScores for treatment effect (0, 1+ 2+ 3+) are based on the staining intensity of the antibody in tumour samples.

^bP indicates the level of significance for the interaction between treatment (C vs CB+CBM) and the biomarker.

^cAnalysis unadjusted.

^dAnalysis adjusted for baseline clinicopathological characteristics.

^eAnalysis adjusted for other biomarkers.